Supuesto ladrón del bolso de la secretaria de Seguridad Nacional es detenido

26 de abril de 2025
EyeMD EMR Healthcare Systems, Inc., a Leading Healthcare Technology Provider for Ophthalmologists, Announces Significant Growth Investment from Performant Capital

26 de abril de 2025
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

26 de abril de 2025

Categorias

Actualidad (16241)
()
Comunidad (2810)
Entretenimiento (2683)
Deportes (1179)
DMV (1510)
Latin News (403)
Latinoamérica y Mundo (3733)
Maryland (1050)
Opinión (2901)
Virginia (891)

Metro Latino

Metro Latino USA

Metro Latino USA es un sitio informativo digital fundado en 2007 en el área de Washington, DC para crear conciencia ciudadana y sumarse a llamados a la acción con las nuevas plataformas disponibles online.

¡Síguenos!

¡Contáctenos!

[email protected]
www.metrolatinusa.com
Lun-Vier : 8:00 am - 5:00 pm

Opinión

Preocupación por la libertad de expresión

Movimiento para reformar el sistema quebrantado de tratados

Diez años de Guantánamo: el prisionero y el fiscal

Derechos humanos en Guatemala

El Golfo Pérsico: Fiel de la balanza

El Golfo Pérsico: Fiel de la balanza

Mitt Romney: ¡Ay Chihuahua!

La expulsión de la Cónsul venezolana en Miami: ¿Quién manda en Washington?

Guatemala: El lado racista del desempleo

Dos años después, terremoto en Haití sacude a la ONU

Supuesto ladrón del bolso de la secretaria de Seguridad Nacional es detenido

EyeMD EMR Healthcare Systems, Inc., a Leading Healthcare Technology Provider for Ophthalmologists, Announces Significant Growth Investment from Performant Capital

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

NSSC Investors Have Opportunity to Lead Napco Security Technologies, Inc. Securities Fraud Lawsuit with the Schall Law Firm

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

Supuesto ladrón del bolso de la secretaria de Seguridad Nacional es detenido

EyeMD EMR Healthcare Systems, Inc., a Leading Healthcare Technology Provider for Ophthalmologists, Announces Significant Growth Investment from Performant Capital

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

NSSC Investors Have Opportunity to Lead Napco Security Technologies, Inc. Securities Fraud Lawsuit with the Schall Law Firm

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

Supuesto ladrón del bolso de la secretaria de Seguridad Nacional es detenido

EyeMD EMR Healthcare Systems, Inc., a Leading Healthcare Technology Provider for Ophthalmologists, Announces Significant Growth Investment from Performant Capital

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

NSSC Investors Have Opportunity to Lead Napco Security Technologies, Inc. Securities Fraud Lawsuit with the Schall Law Firm

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer